Although our data provide the first preclinical proof of concept for the TDP-43-targeting approach using gapmer ASOs for the treatment of ALS/FTD, a limitation of this study is the lack of data on the toxic side effects that might result from the reduction of TDP-43. The gene discussed is TARDBP; the disease is amyotrophic lateral sclerosis.